CognitiveNot FDA ApprovedClinical Trials

Selank

Also known as Selanc, TP-7

A synthetic peptide derived from tuftsin, an immunomodulatory peptide. Approved in Russia for anxiety and nootropic effects.

Approved in Russia - Not FDA approved (Removed from Category 2 Sept 2024)

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

250-500 mcg intranasal 2-3x daily

Frequency

2-3x daily

Duration

14-21 days typical

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 250-500 mcg intranasal 2-3x daily via Intranasal spray (most common) or subcutaneous injection, 2-3x daily. Dose range: 200-750 mcg per dose. Duration: 14-21 days typical.

Timing & Administration

Administer via Intranasal spray (most common) or subcutaneous injection. Frequency: 2-3x daily.

Mechanism of Action

Modulates BDNF expression, influences serotonin and dopamine metabolism, affects GABAergic system, possesses immunomodulatory properties from tuftsin backbone.

Research Summary

Evidence level: clinical trials. Clinical status: Approved in Russia - Not FDA approved (Removed from Category 2 Sept 2024).

Side Effects & Safety

Important Warnings

  • Non-sedative and non-addictive
  • May potentiate benzodiazepine effects.
Nasal irritation (spray)
headache
nausea
fatigue

References

No references available.